市场调查报告书
商品编码
1395828
智慧胰岛素笔针全球市场规模、占有率、产业趋势分析报告:按可用性、按产品、按最终用户、按地区、展望和预测,2023-2030 年Global Smart Insulin Pens Market Size, Share & Industry Trends Analysis Report By Usability, By Product, By End User (Hospitals & Clinics, Ambulatory Surgical Centers, and Home Care Settings), By Regional Outlook and Forecast, 2023 - 2030 |
预计到 2030 年,智慧胰岛素笔针市场规模将达到 1.998 亿美元,预测期内复合年增长率为 10.5%。 2022年市场规模为79.78万台,成长率为9.9%(2019-2022年)。
根据 KBV 基数矩阵中的分析,F. Hoffmann-La Roche Ltd 是该市场的先驱。 2021 年 4 月,F. Hoffmann La Roche 与诺和诺德建立合作伙伴关係,为糖尿病患者开发资料收集解决方案。根据这项合作关係,罗氏将把 mySugr 的日誌与诺和诺德的联网连网型胰岛素笔针集成,提供增强的资料集和改进的见解。诺和诺德公司、雅培实验室和美敦力公司等公司是市场上的主要创新者。
COVID-19 影响分析
包括智慧胰岛素笔针在内的医疗设备的生产和分销受到了疫情导致的全球支援链中断的影响。製造成本上升,导致缺货延误。大流行的经济不确定性给个人和医疗保健系统造成了财务困难。然而,在大流行期间,最大限度地减少面对面互动的需要加速了远端监控和远端医疗解决方案的采用。这些笔具有连接功能,有助于促进远端糖尿病管理和咨询。因此,疫情对市场影响不大。
市场成长要素
对连接和即时监控设备的需求不断增长
笔的互联程度越来越高,用户可以将其设备与智慧型手机和其他行动应用程式同步。这种连接可实现即时资料传输,使患者更轻鬆地追踪其胰岛素给药并与医疗保健提供者共用相关资讯。此外,为了解决胰岛素耗尽的问题,一些智慧笔还配备了一个感测器,用于监测药筒中剩余的胰岛素量。此功能可让用户规划及时补充并最大限度地减少意外胰岛素短缺的风险。因此,医疗保健设备对连接和即时监控的需求不断增长,也加速了对这些笔的需求。
对符合监管核准和标准的产品的需求增加
监管部门的核准和对标准的遵守可以增强消费者的信心。这些遵守行业标准并满足监管要求的笔更有可能被患者和医疗保健提供者采用。此外,医疗保健提供者、保险公司和其他相关人员更有可能推荐和支持这些已获得监管部门批准的笔。监管机构制定涵盖设备设计、性能和製造流程的标准。这些标准确保了我们的笔始终如一的品质和可靠性。因此,监管核准和标准是市场成长的关键驱动力。
市场抑制因素
初期成本高且保险范围有限
购买这些设备的初期成本可能会阻止对价格敏感或经济拮据的糖尿病患者。购买智慧型胰岛素笔的成本,尤其是具有尖端功能的先进第二代设备,可能成为许多潜在用户使用的障碍。此外,技术先进的产品价格相对昂贵,因此并非所有保险公司都会报销。在某些地区,保险公司可能只为这些笔提供部分承保或完全不承保。因此,有限的保险范围和高昂的初期成本可能会成为普及这些笔的障碍,并阻碍市场成长。
可用性视角
根据易用性,市场可分为预填充型和可重复使用型。在2022年的市场中,可重复使用的细分市场呈现显着的成长速度。可重复使用的笔比预装笔产生的塑胶废弃物更少,预装笔需要在每个笔芯后处理整个设备。对于有环保意识的人来说,这可能是个重要因素。可重复使用的笔在给药调整方面提供了更大的弹性,允许使用者自订胰岛素给药以满足他们的需求。可可重复使用笔的使用者可以从更广泛的胰岛素类型和品牌中进行选择,从而为他们提供更多选择,根据自己的需求客製化治疗方案。
产品展望
依产品划分,市场分为第二代钢笔和第一代钢笔。第二代笔细分市场在2022年获得了可观的市场成长率。第二代笔提供了更先进的连接选项,包括与行动应用程式、云端储存和远端监控系统的无缝整合。这使得能够与医疗保健提供者、看护者和家庭成员进行即时资料共用。第二代笔的先进功能和以使用者为中心的设计加深了使用者的参与。这些好处增加了对这些产品的需求。
最终用户前景
依最终用户划分,市场分为医院/诊所、门诊手术中心和家庭护理设施。在2022年的市场中,居家医疗领域获得了很大的收益占有率。由于世界上大多数糖尿病患者集中在老年人口,居家照护环境中的胰岛素注射笔预计将在未来几年获得巨大的关注。在家使用胰岛素笔可以帮助减少就诊次数,并为患者节省大量金钱和时间。这些笔是在家给药胰岛素的最佳选择,因为它们非常便携。
区域展望
从区域来看,我们对北美、欧洲、亚太地区和拉丁美洲地区的市场进行了分析。 2022 年,北美收益占有率最大。北美对智慧胰岛素笔针的需求增加是由于糖尿病盛行率不断上升、该地区对数位健康解决方案的亲和性、保险覆盖范围以及医疗保健专业人员对这些设备的推荐。此外,北美市场是医疗保健技术领域的创新和竞争中心。这种环境正在导致更先进和用户友好的笔的开发,进一步刺激需求。
The Global Smart Insulin Pens Market size is expected to reach $199.8 million by 2030, rising at a market growth of 10.5% CAGR during the forecast period. In the year 2022, the market attained a volume of 797.8 thousand units experiencing a growth of 9.9% (2019-2022).
Consumers have been inclining towards devices that offer real-time insulin monitoring for better diabetes management. The Second generation smart insulin pens offer more advanced connectivity options, such as seamless integration with mobile apps, cloud storage, and remote monitoring systems which fulfils the need. Consequently, the second generation pens segment would account for nearly 40% of the total market share by 2030. These pens often have more sophisticated data analysis capabilities, allowing users to monitor trends in their insulin usage and glucose levels. The advanced features and user-centric design of second-generation pens foster greater user engagement. These benefits have increased the demand for these products.
The major strategies followed by the market participants are Partnerships as the key developmental strategy to keep pace with the changing demands of end users. For instance, in April, 2022, Ypsomed AG entered a partnership with Abbott, to develop automated insulin delivery solutions. The partnership reinforces the company's commitment to improving diabetes management for patients around the globe. Moreover, in May, 2021, Eli Lilly And Company came into partnership with Roche, to develop diabetes management solutions. Under the partnership, Eli Lilly And Company would combine its Tempo Pen and Tempo Smart Button with a compatible diabetes management platform offered by Roche to develop a comprehensive diabetes management solution for patients around the globe.
Based on the Analysis presented in the KBV Cardinal matrix; F. Hoffmann-La Roche Ltd is the forerunner in the Market. In April, 2021, F. Hoffmann-La Roche Ltd signed a partnership with Novo Nordisk, to develop solutions for data collection of diabetes patients. Under the partnership, Roche would integrate its mySugr's Logbook with Novo Nordisk's connected insulin pens to deliver an enhanced data set along with improved insights. Companies such as Novo Nordisk A/S, Abbott Laboratories and Medtronic PLC are some of the key innovators in Market.
COVID 19 Impact Analysis
Smart insulin pens and other medical device production and distribution were impacted by the pandemic's disruption of global supply chains. Production costs went up, and there were shortages and delays. Financial hardships for both individuals and healthcare systems resulted from the pandemic's economic uncertainty. However, the need to minimize in-person interactions during the pandemic accelerated the adoption of remote monitoring and telehealth solutions. These pens, equipped with connectivity features, played a role in facilitating remote diabetes management and consultations. Therefore, the pandemic had a moderate effect on the market.
Market Growth Factors
Growing demand for connectivity and real-time monitoring devices
The pens have become more interconnected, allowing users to sync their devices with smartphones and other mobile applications. This connectivity enables real-time data transfer, making it easier for patients to keep track of their insulin administration and share relevant information with their healthcare providers. Additionally, in an effort to address the challenge of insulin depletion, some smart pens incorporate sensors that monitor the amount of insulin remaining in the cartridge. This feature enables users to plan for timely refills, minimizing the risk of running out of insulin unexpectedly. Therefore, the rising demand for connectivity and real-time monitoring in healthcare devices is accelerating the demand for these pens as well.
Increasing demand for products meeting regulatory approvals and standards
Regulatory approvals and adherence to standards build consumer trust. Adhering to industry standards and meeting regulatory requirements, these pens are more likely to be adopted by patients and healthcare providers. Moreover, healthcare providers, insurers, and other stakeholders are more inclined to recommend and support these pens that have obtained regulatory clearance. Regulatory agencies establish standards encompassing device design, performance, and manufacturing processes. These standards ensure the consistent quality and reliability of the pens. Thus, regulatory approvals and standards are critical drivers of growth in the market.
Market Restraining Factors
High initial costs and limited insurance coverage
The upfront expense of acquiring these devices may deter individuals with diabetes who are price-sensitive or have limited financial resources. The cost of purchasing a smart insulin pen, particularly advanced second-generation devices with cutting-edge features, can be a barrier to access for many potential users. Moreover, not every insurance company reimburses for technologically advanced products as these are comparatively more expensive. In some regions, insurance providers may offer only partial or no coverage for these pens. Consequently, the limited insurance coverage and high initial cost are barriers to the widespread adoption of these pens and can hinder their market growth.
Usability Outlook
By usability, the market is divided into prefilled and reusable. The reusable segment garnered a remarkable growth rate in the market in 2022. Reusable pens generate less plastic waste than prefilled pens, which require the disposal of the entire device with each cartridge. For people who care about the environment, this may be a crucial factor. Reusable pens offer greater flexibility in dosage adjustment, allowing users to customize their insulin doses as needed, which may be particularly valuable for individuals with variable insulin requirements. Users of reusable pens can select from a broader range of insulin types and brands, giving them more options to tailor their treatment to their needs.
Product Outlook
Based on product, the market is characterized into second generation pens and first generation pens. The second generation pens segment procured a considerable growth rate in the market in 2022. Second-generation pens offer more advanced connectivity options, such as seamless integration with mobile apps, cloud storage, and remote monitoring systems. This enables real-time data sharing with healthcare providers, caregivers, and family members. The advanced features and user-centric design of second-generation pens foster greater user engagement. These benefits have increased the demand for these products.
End User Outlook
Based on end-user, the market is segmented into hospitals & clinics, ambulatory surgical centers, and home care settings. The home care settings segment acquired a substantial revenue share in the market in 2022. These pens for insulin delivery in homecare settings are expected to gain enormous traction in the upcoming years, as most of the world's diabetes cases are concentrated among the elderly population. Insulin pens used at home can help lower the number of hospital visits, saving patients a great deal of money and time. These pens are the best option for administering insulin at home because of their high level of portability.
Regional Outlook
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment recorded the largest revenue share in the market in 2022. The increasing demand for smart insulin pens in North America can be attributed to the growing prevalence of diabetes, the region's affinity for digital health solutions, insurance coverage, and the endorsement of these devices by healthcare professionals. Moreover, the North America market is a hub for innovation and competition in the healthcare technology sector. This environment has led to the development of more advanced and user-friendly pens, further stimulating demand.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, Eli Lilly And Company, Novo Nordisk A/S, F. Hoffmann-La Roche Ltd, Emperra GmbH, Jiangsu Delfu Medical Device Co.,Ltd, Abbott Laboratories and Ypsomed AG
Strategies Deployed in Smart Insulin Pens Market
Oct-2023: Novo Nordisk A/S announced the acquisition of Biocorp, a French drug delivery device maker. The acquisition complements and strengthens Novo Nordisk's connected delivery solutions.
Sep-2023: Abbott Laboratories signed an agreement to acquire Bigfoot, a smart insulin management systems developer. The acquisition strengthens Abbott's capability to deliver improved diabetes management solutions.
Sep-2022: Medtronic PLC released the Smart MDI system, a glucose management system for patients who are going through multiple daily injections. The system leverages Medtronic's InPen smart insulin pen and Guardian 4 smart continuous glucose monitoring (CGM) system to deliver real-time glucose values and insulin doses.
Apr-2022: Ypsomed AG entered a partnership with Abbott, a medical device company, to develop automated insulin delivery solutions. The partnership reinforces the company's commitment to improving diabetes management for patients around the globe.
Mar-2022: Novo Nordisk A/S introduced NovoPen Echo Plus and NovoPen 6 smart self-injection insulin pens. The two pens are used to display dosing information and can be paired with a compatible app to send the information to healthcare professionals, thereby facilitating remote patient monitoring.
May-2021: Eli Lilly And Company came into partnership with Roche, a global pharmaceutical company, to develop diabetes management solutions. Under the partnership, Eli Lilly And Company would combine its Tempo Pen and Tempo Smart Button with a compatible diabetes management platform offered by Roche to develop a comprehensive diabetes management solution for patients around the globe.
Apr-2021: F. Hoffmann-La Roche Ltd signed a partnership with Novo Nordisk, a Danish pharmaceutical company, to develop solutions for data collection of diabetes patients. Under the partnership, Roche would integrate its mySugr's Logbook with Novo Nordisk's connected insulin pens to deliver an enhanced data set along with improved insights.
Market Segments covered in the Report:
By Usability (Volume, Thousand Units, Revenue, USD Million, 2019-30)
By Product
By End User (Volume, Thousand Units, Revenue, USD Million, 2019-30)
By Geography (Volume, Thousand Units, Revenue, USD Million, 2019-30)
Companies Profiled
Unique Offerings from KBV Research